[Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy].

Bull Cancer

AP-HP, hôpital Saint-Antoine, Sorbonne Université, service d'oncologie médicale, 75012 Paris, France; Sorbonne Université, Inserm, Unité Mixte de Recherche Scientifique 938, Centre de recherche Saint-Antoine et SIRIC CURAMUS, Équipe Instabilité des Microsatellites et Cancer, Équipe labellisée par la Ligue nationale contre le Cancer, 75012 Paris, France.

Published: January 2022

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.bulcan.2021.08.010	DOI Listing

Publication Analysis

Top Keywords

[drug approval

approval nivolumab

nivolumab ipilimumab

ipilimumab patients

patients msi

msi -high

-high metastatic

metastatic colorectal

colorectal cancer

cancer treated

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!